BRPI0411973A - forma polimórfica a do ácido 4-[6-acetil-3-[3-(4-acetil-3-hidróxi-2-propilfeniltio)pro póxi]-2-propilfenóxi]butìrico - Google Patents

forma polimórfica a do ácido 4-[6-acetil-3-[3-(4-acetil-3-hidróxi-2-propilfeniltio)pro póxi]-2-propilfenóxi]butìrico

Info

Publication number
BRPI0411973A
BRPI0411973A BRPI0411973-8A BRPI0411973A BRPI0411973A BR PI0411973 A BRPI0411973 A BR PI0411973A BR PI0411973 A BRPI0411973 A BR PI0411973A BR PI0411973 A BRPI0411973 A BR PI0411973A
Authority
BR
Brazil
Prior art keywords
acetyl
propylphenoxy
hydroxy
propylphenylthio
propoxy
Prior art date
Application number
BRPI0411973-8A
Other languages
English (en)
Inventor
Kenneth Walter Locke
David Gregory Roe
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of BRPI0411973A publication Critical patent/BRPI0411973A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMA POLIMóRFICA A DO áCIDO 4-¢6-ACETIL-3-¢3-(4-ACETIL-3-HIDRóXI-2-PROPILFENILTIO)PRO PóXI!-2-PROPILFENóXI!BUTìRICO". A presente invenção refere-se à composição farmacêutica, compreendendo: um composto de fórmula (1) na forma cristalina polimórfica A: (1) junto com um veículo ou excipiente farmaceuticamente aceitável, onde o composto de fórmula (1) está presente na forma polimórfica A (vide, por exemplo, a figura 6) substancialmente isento de outras formas polimórficas.
BRPI0411973-8A 2003-06-24 2004-06-24 forma polimórfica a do ácido 4-[6-acetil-3-[3-(4-acetil-3-hidróxi-2-propilfeniltio)pro póxi]-2-propilfenóxi]butìrico BRPI0411973A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/601,862 US7064146B2 (en) 2003-06-24 2003-06-24 Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use
PCT/US2004/020154 WO2005000243A2 (en) 2003-06-24 2004-06-24 The polymorphic form a of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butryric acid

Publications (1)

Publication Number Publication Date
BRPI0411973A true BRPI0411973A (pt) 2006-08-29

Family

ID=33539463

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411973-8A BRPI0411973A (pt) 2003-06-24 2004-06-24 forma polimórfica a do ácido 4-[6-acetil-3-[3-(4-acetil-3-hidróxi-2-propilfeniltio)pro póxi]-2-propilfenóxi]butìrico

Country Status (11)

Country Link
US (3) US7064146B2 (pt)
EP (1) EP1636176A4 (pt)
JP (2) JP5518280B2 (pt)
KR (1) KR101120408B1 (pt)
CN (1) CN1812968B (pt)
BR (1) BRPI0411973A (pt)
CA (1) CA2530583C (pt)
NO (1) NO20060379L (pt)
NZ (1) NZ544319A (pt)
RU (1) RU2317979C2 (pt)
WO (1) WO2005000243A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060854B2 (en) * 2003-06-24 2006-06-13 Medicinova, Inc. Process for making polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid
US7064146B2 (en) * 2003-06-24 2006-06-20 Medicinova, Inc. Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use
RU2388466C2 (ru) 2004-04-27 2010-05-10 Медисинова, Инк. Производные феноксиалкилкарбоновых кислот при лечении воспалительных заболеваний
US8962687B2 (en) 2012-12-05 2015-02-24 Medicinova, Inc. Method of treating liver disorders
US8835499B2 (en) 2011-12-08 2014-09-16 Medicinova, Inc. Method of treating non-alcoholic fatty liver disease and steatohepatitis
US20150031769A1 (en) 2013-07-25 2015-01-29 Medicinova, Inc. Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels
US9346754B2 (en) 2014-05-08 2016-05-24 Medicinova, Inc. Method of treating advanced non-alcoholic steatohepatitis
US20150321989A1 (en) 2014-05-08 2015-11-12 Medicinova, Inc. Method of treating idiopathic pulmonary fibrosis
KR102435793B1 (ko) * 2014-06-02 2022-08-25 메디시노바, 인크. 섬유증의 억제 또는 치료 방법
WO2016033094A1 (en) 2014-08-25 2016-03-03 Aimmune Therapeutics, Inc. Egg protein formulations and methods of manufacture thereof
US20160220710A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Compositions and methods for delivering pharmaceutical agents
CA3217719A1 (en) 2021-05-28 2022-12-01 Kazuko Matsuda Phenoxyalkylcarboxylic acid derivatives and their use in lowering triglyceride levels
JP7478895B1 (ja) 2022-11-30 2024-05-07 花王株式会社 痒みの予防又は改善剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5858146A (ja) * 1981-10-05 1983-04-06 Tanabe Seiyaku Co Ltd 速放性マイクロカプセル
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
JPH07116125B2 (ja) * 1988-03-07 1995-12-13 杏林製薬株式会社 フェノキシアルキルカルボン酸誘導体及びその製造法
US4985585A (en) * 1988-03-07 1991-01-15 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process for their preparations
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
JPH06345682A (ja) * 1993-06-11 1994-12-20 Kyorin Pharmaceut Co Ltd カルボン酸誘導体
JP3773064B2 (ja) * 1994-09-13 2006-05-10 杏林製薬株式会社 フェノキシアルキルカルボン酸誘導体の製造法
US5639475A (en) * 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
JPH1179985A (ja) 1997-09-01 1999-03-23 Kyorin Pharmaceut Co Ltd 喘息治療用の粉末吸入剤
US7060854B2 (en) * 2003-06-24 2006-06-13 Medicinova, Inc. Process for making polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid
US7064146B2 (en) * 2003-06-24 2006-06-20 Medicinova, Inc. Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use

Also Published As

Publication number Publication date
RU2006101871A (ru) 2006-07-27
NO20060379L (no) 2006-03-24
CA2530583A1 (en) 2005-01-06
KR20060030484A (ko) 2006-04-10
US7064146B2 (en) 2006-06-20
JP2007524624A (ja) 2007-08-30
EP1636176A4 (en) 2010-03-31
NZ544319A (en) 2008-12-24
CN1812968A (zh) 2006-08-02
CN1812968B (zh) 2016-07-27
US7728169B2 (en) 2010-06-01
WO2005000243A2 (en) 2005-01-06
EP1636176A2 (en) 2006-03-22
US7365224B2 (en) 2008-04-29
JP2014097989A (ja) 2014-05-29
KR101120408B1 (ko) 2012-03-15
US20080292698A1 (en) 2008-11-27
RU2317979C2 (ru) 2008-02-27
US20060135604A1 (en) 2006-06-22
CA2530583C (en) 2010-08-10
WO2005000243A3 (en) 2005-04-28
US20040266878A1 (en) 2004-12-30
JP5518280B2 (ja) 2014-06-11

Similar Documents

Publication Publication Date Title
BRPI0411973A (pt) forma polimórfica a do ácido 4-[6-acetil-3-[3-(4-acetil-3-hidróxi-2-propilfeniltio)pro póxi]-2-propilfenóxi]butìrico
BRPI0500480A (pt) processo para a sìntese de (1s)-4,5-dimetóxi- 1-(metilaminometil)-benzociclobutano e sais de adição deste, e aplicação na sìntese de ivabradina e sais de adição desta com um ácido farmaceuticamente aceitável
BR0213931A (pt) Forma polimórfica de rimonabant, processo para sua preparação e composições farmacêuticas contendo-as
BRPI0500393A (pt) Processo para a sìntese e forma cristalina de agomelatina e composições farmacêuticas contendo-a
BR0314071A (pt) Derivados de pró-droga de 1,3-diamino-2-hidroxipropano
BR0214031A (pt) Compostos de heteroarila azabicìclico substituìdos para o tratamento de doenças
EA200702498A1 (ru) N-(пиридин-2-ил)сульфонамидные производные
BRPI0500585B8 (pt) processo para a síntese de ivabradina e sais de adição desta com um ácido farmaceuticamente aceitável
BRPI0412659A (pt) isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
PA8638201A1 (es) Forma cristalina alfa del ranelato de estroncio procedimiento para su preparacion y composiciones farmaceuticas que la contienen
BRPI0608245A2 (pt) compostos; processo para a sua fabricação; composições farmacêuticas; método para o tratamento e/ou prevenção de doenças que estejam associadas à modulação de receptores de sst subtipo 5 e uso dos compostos
BR0317005A (pt) Processo para a preparação de compostos ativos opticamente puros
DE602006019499D1 (de) Eine pentakis(dimethylamino)disilanvorstufe enthaltende verbindung, und verfahren zu deren herstellung
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.
BR0213760A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
BR0116332A (pt) Processo para o aumento da estabilidade
BR9708233A (pt) Processo para sìntese de um composto e composto.
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
WO2005000242A3 (en) Process for making polymorphic form a of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]butyric acid
BR9713207A (pt) Derivados de 3-mercaptoacetilamino-1,5-substituìdo-2-oxo-azepan uteis como inibidores de metaloproteinase de matriz
BR0316702A (pt) xprocesso para preparação de (s)-pantoprazol
BR0112745A (pt) Processo para a preparação de arilacetilaminotiazóis
BRPI0416746A (pt) processo de sìntese do perindopril e de seus sais farmaceuticamente aceitáveis
BR0214742A (pt) Polimorfo cristalino de cloridrato de venlafaxina e métodos para sua preparação

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.